Department of Epidemiology, University of Michigan, Ann Arbor, MI, 48109, USA.
Department of Anthropology, University of Michigan, Ann Arbor, MI, 48109, USA.
BMC Health Serv Res. 2023 Nov 23;23(1):1290. doi: 10.1186/s12913-023-10334-9.
Sexually transmitted infections (STIs) like chlamydia, gonorrhea, syphilis, and trichomoniasis contribute significantly to global morbidity and mortality. Researchers are pursuing vaccines for these STIs, and a clinical trial is currently underway for a chlamydia vaccine. However, there is little research available on individuals' willingness to receive chlamydia, gonorrhea, syphilis, and trichomoniasis vaccines. The purpose of this analysis was to map the existing literature we have on individuals' willingness to receive these bacterial/parasitic STI vaccines and understand what information on vaccine acceptability is still needed.
We searched seven databases for literature on STI vaccine acceptability, then conducted title/abstract and full-text reviews to assess eligibility. All reviews and abstractions were conducted blindly by two reviewers, with discrepancies settled by discussion or the input of a third reviewer.
Eight of the original 2,259 texts of interest met inclusion criteria. After data abstraction, we found that gonorrhea was the most commonly examined, followed by chlamydia and syphilis. Trichomoniasis vaccine acceptability was not reported. Most texts reported high acceptability, but there did not appear to be data describing how vaccine characteristics affect acceptability. Similarly, while the literature covers a variety of populations, most of the study populations were based out of the United States or Canada and were patrons of healthcare facilities or participants from a larger health intervention study. Therefore, more information is needed on populations outside North America, and on groups with lower healthcare access and utilization.
As the incidence of bacterial and parasitic STIs increase, and as we grow nearer vaccines for these illnesses, understanding how likely the public is to accept and receive these vaccines is crucial to their success. While the existing literature describes STI vaccine acceptability in a variety of populations, their overall number is small. More research into STI vaccine acceptability outside of North America, and especially examining how factors like number of doses, timing, and cost influence vaccine acceptability is needed to ensure effective future vaccine rollouts.
淋病、衣原体、梅毒和滴虫病等性传播感染（STI）对全球发病率和死亡率有重大影响。研究人员正在为这些 STI 开发疫苗，目前正在进行衣原体疫苗的临床试验。然而，关于个人接种衣原体、淋病、梅毒和滴虫病疫苗的意愿，研究甚少。本分析旨在绘制现有关于个人接种这些细菌/寄生虫性 STI 疫苗意愿的文献，并了解疫苗可接受性方面仍需要哪些信息。
我们在七个数据库中搜索关于 STI 疫苗可接受性的文献，然后进行标题/摘要和全文审查以评估合格性。所有审查和摘要均由两名评审员进行盲审，如有分歧则通过讨论或第三名评审员的意见解决。
从最初的 2259 篇相关文章中，有 8 篇符合纳入标准。在数据提取后，我们发现淋病是最常被检查的，其次是衣原体和梅毒。滴虫病疫苗可接受性未被报道。大多数文本报告了高可接受性，但似乎没有数据描述疫苗特征如何影响可接受性。同样，虽然文献涵盖了各种人群，但大多数研究人群来自北美以外的国家和地区，是医疗保健机构的患者或更大健康干预研究的参与者。因此，需要更多关于北美以外人群的信息，以及关于医疗保健获取和利用较低的群体的信息。
随着细菌和寄生虫性 STI 的发病率上升，并且我们越来越接近针对这些疾病的疫苗，了解公众对这些疫苗的接受和接种意愿至关重要。虽然现有文献描述了各种人群中的 STI 疫苗可接受性，但数量很少。需要更多关于北美以外地区 STI 疫苗可接受性的研究，特别是研究诸如剂量、时间和成本等因素如何影响疫苗可接受性，以确保未来疫苗的有效推出。
